<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02747381</url>
  </required_header>
  <id_info>
    <org_study_id>CL (1122)</org_study_id>
    <nct_id>NCT02747381</nct_id>
  </id_info>
  <brief_title>The Effect of Vitamin D Supplementation on the Pulmonary Functions of Adult Asthmatic Egyptian Patients</brief_title>
  <official_title>The Effect of Vitamin D Supplementation on the Pulmonary Functions of Adult Asthmatic Egyptian Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of vitamin D supplementation in the form of Alfacalcidol on&#xD;
      the the pulmonary function of adult asthmatic Egyptian patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthmatic patients are recruited and divided into two groups. One receives Alfacalcidol&#xD;
      beside their normal medications while the other acts as a control group receiving the normal&#xD;
      asthma medication.&#xD;
&#xD;
      Both groups are followed up for four months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>forced expiratory volume % predicted values</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive Alfacalcidol 1 mcg daily for 4 months beside the conventional asthma medications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Asthmatic patients receiving conventional asthma medications</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alfacalcidol</intervention_name>
    <description>1-alpha hydroxy cholecalciferol 1 mcg</description>
    <arm_group_label>intervention</arm_group_label>
    <other_name>One alpha</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with asthma&#xD;
&#xD;
          2. Non-smokers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Liver impairment&#xD;
&#xD;
          2. Kidney impairment&#xD;
&#xD;
          3. Patients receiving digoxin&#xD;
&#xD;
          4. Known hypersensitivity to 1Î±-hydroxyvitamin D3, vitamin D or any of its analogues and&#xD;
             derivatives&#xD;
&#xD;
          5. Hypercalcaemia&#xD;
&#xD;
          6. Hyperphosphatemia&#xD;
&#xD;
          7. Pregnancy and breast-feeding&#xD;
&#xD;
          8. Patients on nutritional supplements with a potential effect on 25(OH)D serum&#xD;
             concentrations&#xD;
&#xD;
          9. Had a History of stones in the urinary tract or diseases of calcium or bone metabolism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amani Ali</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of pharmacy, Cairo university</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Amani Mohamed</investigator_full_name>
    <investigator_title>Teaching assisstant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfacalcidol</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

